Using TRIPS flexibilities to facilitate access to medicines;Cómo utilizar los aspectos flexibles de los ADPIC para facilitar el acceso a los medicamentos

Bulletin of the World Health Organization

Volumn 91, Issue 7, 2013, Pages 533-539

  Nicol, Dianne ^a   Owoeye, Olasupo ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; INCENTIVE; INTELLECTUAL PROPERTY RIGHTS; INTERNATIONAL LAW; LEGISLATION; MANUFACTURING; PHARMACEUTICAL INDUSTRY;

ARTICLE; AUSTRALIA; CLINICAL PROTOCOL; DECISION MAKING; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; INCOME; LAW; MEDICAL PRACTICE; MEDICAL SERVICE; MEDICAL SOCIETY; ORGANIZATIONAL DOWNSIZING; ORGANIZATIONAL EFFICIENCY; TRADE RELATED ASPECTS OF INTELLECTUAL PROPERTY RIGHT;

AUSTRALIA; HEALTH SERVICES ACCESSIBILITY; HUMANS; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS; POLICY MAKING; POVERTY; WORLD HEALTH;

AUSTRALIA;

EID: 84879570744     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.12.115865     Document Type: Article

References (50)

1. World Trade Organization [Internet]. Agreement on Trade-Related Aspects of Intellectual Property Rights: Annex 1C of the Marrakesh Agreement establishing the World Trade Organization, signed in Marrakesh, Morocco on 15 April 1994. Geneva: WTO; 1994. Available from: http://www.wto.org/english/tratop_e/trips_e/t_agm0_e.htm [accessed 6 April 2013].
2. Correa CM. Intellectual property, WTO and developing countries: the TRIPS Agreement and policy options. London, New York & Penang: Zed Books & Third World Network; 2000.
3. Matthews D. Globalising intellectual property rights: the TRIPS Agreement. London: Routledge; 2002.
4. Sell SK. Private power, public law: the globalisation of intellectual property rights. Cambridge: Cambridge University Press; 2003.
5. Mercurio B. Reconceptualising the debate on intellectual property rights and economic development. Law Develop Rev 2012;3:65-107.
6. Pacon AM. What will TRIPS do for developing countries? In: Beier F, Schricker G, editors. From GATT to TRIPS - the Agreement on Trade-Related Aspects of Intellectual Property Rights, studies in industrial property and copyright law. Munich: VCH Verlagsgesellschaft mbH; 1996.
7. Drahos P. The global ratchet for intellectual property rights: why it fails as policy and what should be done about it. New York: Open Society Institute; 2003. Available from: https://researchers.anu.edu.au/researchers/drahos-pf [accessed 6 April 2013].
8. Islam MT. TRIPS Agreement and public health: implications and challenges for Bangladesh. Int Trade Law Reg 2011;17:10-38.
9. Cerón A, Godoy AS. Intellectual property and access to medicines: an analysis of legislation in Central America. Bull World Health Organ 2009;87:787-93. doi: http://dx.doi.org/10.2471/BLT.08.056010 PMID:19876546
10. Oliveira MA, Bermudez JA, Chaves GC, Velásquez G. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health? Bull World Health Organ 2004;82:815-21.PMID:15640916
11. United Nations Economic and Social Council. Statement by the Committee on Economic, Social and Cultural Rights: human rights and intellectual property. Geneva: United Nations; 2001 (Document E/C.12/2001/15).
12. Resolution UN A/RES/65/277. Political Declaration on HIV and AIDS: intensifying our efforts to eliminate HIV and AIDS. New York: United Nations General Assembly; 10 June 2011.
13. Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property. Geneva: World Health Organization; 2011.
14. Report of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property. Geneva: World Health Organization; 2008 (Document A61/9).
15. Promoting access to medical technologies and innovation: intersections between public health, intellectual property and trade. Geneva: World Health Organization, World Intellectual Property Organization & World Trade Organization; 2013.
16. Zero draft global plan for the prevention and control of non-communicable diseases 2013-2020. Geneva: World Health Organization; 2013 (EB132/7).
17. WIPO's legal and technical assistance to developing countries for the implementation of the TRIPS Agreement from January 1, 1996 to March 31, 1999. Geneva: World Intellectual Property Organization; 1999.
18. World Trade Organization [Internet]. Doha ministerial declaration on the TRIPS Agreement and public health, WT/MIN(01)/DEC/1: adopted in Doha on 14 November 2001. Geneva: WTO; 2013. Available from: http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm [accessed 7 April 2013].
19. Reichman JH. Comment: compulsory licensing of patented pharmaceutical inventions: evaluating the options. J Law Med Ethics 2009;37:247-63. doi: http://dx.doi.org/10.1111/j.1748-720X.2009.00369.x PMID:19493070
20. Beall R, Kuhn R. Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis. PLoS Med 2012;9:e1001154. doi: http://dx.doi.org/10.1371/journal.pmed.1001154 PMID:22253577
21. Facts and evidences on the 10 burning issues related to the government use of patents on three patented essential drugs in Thailand. Bangkok: Ministry of Public Health and National Health Security Office; 2007. Available from: http://apps.who.int/medicinedocs/documents/s18718en/s18718en.pdf [accessed 4 March 2013].
22. Lybecker KM, Fowler E. Compulsory licensing in Canada and Thailand: comparing regimes to ensure legitimate use of the WTO rules. J Law Med Ethics 2009;37:222-39. doi: http://dx.doi.org/10.1111/j.1748-720X.2009.00367.x PMID:19493068
23. World Trade Organization [Internet]. Implementation of paragraph 6 of the Doha declaration on the TRIPS Agreement and public health,WT/L/540: General Council Decision of 30 August 2003. Geneva: WTO; 2013. Available from: https://docs.wto.org/dol2fe/Pages/FE_Search/FE_S_S001.aspx [accessed 7 April 2013].
24. World Trade Organization [Internet]. Amendment of the TRIPS Agreement, WT/L/641: decision of 6 December 2005. Geneva: WTO; 2013. Available from: https://docs.wto.org/dol2fe/Pages/FE_Search/FE_S_S001.aspx [accessed 4 April 2013].
25. Mitchell A, Voon T. The TRIPS waiver as a recognition of public health concerns in the WTO. In: Pogge T, Rimmer M, Rubenstein K, editors. Incentives for global public health: patent law and access to essential medicines. New York: Cambridge University Press; 2010.
26. Kuhn R, Beall RF. The time for pharmaceutical compulsory licensing has expired. Nat Med 2012;18:1168. doi: http://dx.doi.org/10.1038/nm0812-1168 PMID:22869177
27. World Trade Organization [Internet]. Members accepting amendment of the TRIPS Agreement, 5 November 2012. Geneva: WTO; 2013. Available from: http://www.wto.org/english/tratop_e/trips_e/amendment_e.htm [accessed 7 April 2013].
28. World Trade Organization [Internet]. Members' laws implementing the 'Paragraph 6' system, 28 February 2011. Geneva: WTO; 2013. Available from: http://www.wto.org/english/tratop_e/trips_e/par6laws_e.htm [accessed 7 April 2013]).
29. Implementation of TRIPS and access to medicines for HIV after January 2016: options and strategies for least developed countries. Geneva: Joint United Nations Programme on HIV/AIDS; 2011 (UNAIDS Technical Brief).
30. Rimmer M. Race against time: the export of essential medicines to Rwanda. Public Health Ethics 2008;1:89-103. doi: http://dx.doi.org/10.1093/phe/phn011
31. World Trade Organization [Internet]. World Trade Organization Council for TRIPS. Annual review of the decision on the implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health, IP/C/63, 18 November 2012. Geneva: WTO; 2013. Available from: http://www.wto.org/english/tratop_e/trips_e/ta_docs_e.htm [accessed 7 April 2013].
32. Young F, Critchley J, Johnstone C, Unwin N. Globalization and the dual disease burden in sub-Saharan Africa. Diabetes Voice 2010;55:30-2.
33. Greene W. The emergence of India's pharmaceutical industry and implications for the US generic drug market. Washington: Office of Economics, US International Trade Commission; 2007 (Working Paper No. 2007-05-A).
34. Kapczynski A. Harmonization and its discontents: a case study of TRIPS implementation in India's pharmaceutical sector. Calif Law Rev 2009;97:1571-649.
35. Bubela T, Fitzgerald GA, Gold ER. Recalibrating intellectual property rights to enhance translational research collaborations. Science Translational Med 2012;4:122cm3.
36. Pogge T. The Health Impact Fund: better pharmaceutical innovations at much lower prices. In: Pogge T, Rimmer M, Rubenstein K, editors. Incentives for global public health: patent law and access to essential medicines. New York: Cambridge University Press; 2010.
37. Fisher WW, Syed T. A prize system as a partial solution to the heath crisis in the developing world. In: Pogge T, Rimmer M, Rubenstein K, editors. Incentives for global public health: patent law and access to essential medicines. New York: Cambridge University Press; 2010.
38. Nicol D, Nielsen J. Opening the dam: patent pools, innovation and access to essential medicines. In: Pogge, T, Rimmer, M, Rubenstein K, editors. Incentives for global public health: patent law and access to essential medicines. New York: Cambridge University Press; 2010.
39. Barton JH. The economics of TRIPS: international trade in information-intensive products. George Washington Int Law Rev 2001;33:473-501.
40. Pharmacogenetics: ethical issues. London: Nuffield Council of Bioethics; 2003.
41. Vaile M. Vaile welcomes breakthrough on access to medicines (media release). 31 August 2003. Canberra: Australian Ministers for Trade, archives 1995 to 2000. Available from: http://www.trademinister.gov.au/releases/2003/mvt067_03.html [accessed 7 April 2013].
42. Hoen EFM. TRIPS, pharmaceutical patents and access to essential medicines: Seattle, Doha and beyond. In: Moatti JP, Coriat B, Souteyrand Y, Barnett B, Dumoulin J, Flori YA. Economics of AIDS and access to HIV/AIDS care in developing countries: issues and challenges. Paris: Agence Nationale de Recherches sur le Sida; 2003.
43. Rimmer M. The Jean Chretien Pledge to Africa Act: patent law and humanitarian aid. Expert Opin Ther Pat 2005;15:889-909.
44. Médecins Sans Frontières [Internet]. Neither expeditious, nor a solution: the WTO August 30th decision is unworkable: an illustration through Canada's Jean Chretien Pledge to Africa. Report prepared for the XVI International AIDS Conference, Toronto, 13-18 August 2006. Geneva & Montreal: Médecins Sans Frontières; 2013. Available from: http://www.doctorswithoutborders.org/news/hiv-aids/WTO_chretien.pdf [accessed 6 April 2013].
45. Canadian HIV/AIDS Legal Network [Internet]. Children can't wait! Dying for drugs in developing countries. Toronto: CHALN; 2013. Available from: http://www.aidslaw.ca/EN/camr/index.htm [accessed 7 April 2013].
46. Wakeley J. The impact of external factors on the effectiveness of compulsory licensing as a means of increasing access to medicines in developing countries. Eur Intellect Prop Rev 2011;33:756-70.
47. Nielsen J, Nicol D. Whither patent use without authorisation in Australia. Fed Law Rev 2008;36:333-64.
48. IP Australia [Internet]. Draft Intellectual Property Laws Amendment Bill 2012. Canberra: Australian Government; 2013. Available from: http://www.ipaustralia.gov.au/about-us/public-consultations/ip-laws-amendment-bill/ [accessed 7 April 2013].
49. Australian Government, IP Australia [Internet]. Explanatory memorandum for exposure draft Intellectual Property Laws Amendment Bill 2012. Canberra: Australian Government; 2013. Available from: http://www.ipaustralia.gov.au/search?q=Explanatory+memorandum+for+exposure+draft+Intellectual+Property+Laws+ [accessed 6 April 2013].
50. Paas K. Compulsory licensing under the TRIPS Agreement - a cruel taunt for developing countries? Eur Intellect Prop Rev 2009;31:609-13.